Is ENGN or DARE more profitable?

Dare Bioscience's return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% Dare Bioscience N/A N/A -46.22%

Is BDTX or DARE more profitable?

Dare Bioscience's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Dare Bioscience N/A N/A -46.22%

Do analysts prefer DARE or LIXT?

Dare Bioscience currently has a consensus price target of $10.00, indicating a potential upside of 395.05%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is DARE or LIXT more profitable?

Dare Bioscience's return on equity of 0.00% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Lixte Biotechnology N/A -134.91% -95.61%

Is DARE or PYXS more profitable?

Dare Bioscience's return on equity of 0.00% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Pyxis Oncology N/A -135.60% -85.00%

Which has better valuation & earnings, PLYX or DARE?

Polaryx Therapeutics has higher earnings, but lower revenue than Dare Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A N/A N/A Dare Bioscience $1.03M 29.38 -$13.40M -$0.95 N/A

Is PLYX or DARE more profitable?

Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Dare Bioscience N/A N/A -46.22%

Dare Bioscience (DARE) Competitors

$2.02 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.03 +0.01 (+0.69%)

As of 06/12/2026 07:59 PM Eastern

Compare

DARE vs. ENGN, BDTX, LIXT, PYXS, and PLYX

Should you buy Dare Bioscience stock or one of its competitors? MarketBeat compares Dare Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dare Bioscience include enGene (ENGN), Black Diamond Therapeutics (BDTX), Lixte Biotechnology (LIXT), Pyxis Oncology (PYXS), and Polaryx Therapeutics (PLYX). These companies are all part of the "pharmaceutical products" industry.

How does Dare Bioscience compare to enGene?

enGene (NASDAQ:ENGN) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

enGene has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market.

enGene currently has a consensus price target of $12.68, suggesting a potential upside of 682.83%. Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 395.05%. Given enGene's higher possible upside, research analysts clearly believe enGene is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

64.2% of enGene shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 10.5% of enGene shares are held by insiders. Comparatively, 4.1% of Dare Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, enGene had 10 more articles in the media than Dare Bioscience. MarketBeat recorded 11 mentions for enGene and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.89 beat enGene's score of 0.08 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Dare Bioscience	Very Positive

Dare Bioscience has higher revenue and earnings than enGene. Dare Bioscience is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A

Dare Bioscience's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Dare Bioscience	N/A	N/A	-46.22%

Summary

enGene and Dare Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 1 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.90 beat Dare Bioscience's score of 1.89 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Very Positive
Dare Bioscience	Very Positive

Black Diamond Therapeutics has a beta of 3.22, suggesting that its share price is 222% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 4.1% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Black Diamond Therapeutics has higher revenue and earnings than Dare Bioscience. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.43	$22.37M	-$0.77	N/A
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A

Dare Bioscience's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Dare Bioscience	N/A	N/A	-46.22%

Black Diamond Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 471.43%. Dare Bioscience has a consensus target price of $10.00, suggesting a potential upside of 395.05%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Black Diamond Therapeutics is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Black Diamond Therapeutics beats Dare Bioscience on 12 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Lixte Biotechnology?

Dare Bioscience (NASDAQ:DARE) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

In the previous week, Lixte Biotechnology had 5 more articles in the media than Dare Bioscience. MarketBeat recorded 6 mentions for Lixte Biotechnology and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.89 beat Lixte Biotechnology's score of 0.02 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Dare Bioscience	Very Positive
Lixte Biotechnology	Neutral

Dare Bioscience currently has a consensus price target of $10.00, indicating a potential upside of 395.05%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lixte Biotechnology has lower revenue, but higher earnings than Dare Bioscience. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 9.5% of Lixte Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dare Bioscience's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Lixte Biotechnology	N/A	-134.91%	-95.61%

Dare Bioscience has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market. Comparatively, Lixte Biotechnology has a beta of 1.27, meaning that its share price is 27% more volatile than the broader market.

Summary

Dare Bioscience beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Pyxis Oncology?

Dare Bioscience (NASDAQ:DARE) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 395.05%. Pyxis Oncology has a consensus price target of $6.83, indicating a potential upside of 288.26%. Given Dare Bioscience's higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Pyxis Oncology had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.89 beat Pyxis Oncology's score of 1.68 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Dare Bioscience	Very Positive
Pyxis Oncology	Very Positive

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Dare Bioscience has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market.

Dare Bioscience's return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Pyxis Oncology	N/A	-135.60%	-85.00%

Dare Bioscience has higher earnings, but lower revenue than Pyxis Oncology. Dare Bioscience is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A
Pyxis Oncology	$13.86M	8.04	-$79.62M	-$1.31	N/A

Summary

Pyxis Oncology beats Dare Bioscience on 8 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Dare Bioscience (NASDAQ:DARE) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Dare Bioscience	N/A	N/A	-46.22%

Polaryx Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 321.94%. Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 395.05%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.89 beat Polaryx Therapeutics' score of 0.44 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Dare Bioscience	Very Positive

Polaryx Therapeutics has higher earnings, but lower revenue than Dare Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A

6.7% of Dare Bioscience shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Dare Bioscience beats Polaryx Therapeutics on 7 of the 9 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DARE vs. The Competition

Export

Metric	Dare Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.26M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-2.13	20.00	24.00	24.42
Price / Sales	29.38	304.30	514.65	112.54
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	10.10	8.32	10.69	6.82
Net Income	-$13.40M	$23.94M	$3.57B	$337.56M
7 Day Performance	9.19%	1.84%	0.61%	1.16%
1 Month Performance	-6.91%	-0.04%	1.56%	3.16%
1 Year Performance	-33.33%	44.82%	25.44%	30.60%

Dare Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DARE Dare Bioscience	2.4034 of 5 stars	$2.02 flat	$10.00 +395.0%	-33.3%	$30.26M	$1.03M	N/A	30	Positive News
ENGN enGene	3.7226 of 5 stars	$1.67 +0.9%	$12.68 +661.7%	-51.4%	$111.54M	N/A	N/A	31
BDTX Black Diamond Therapeutics	3.6152 of 5 stars	$1.93 +4.1%	$10.00 +419.5%	-24.2%	$109.73M	$70M	N/A	90	Positive News
LIXT Lixte Biotechnology	0.2612 of 5 stars	$7.28 +9.5%	N/A	+443.0%	$108.60M	N/A	N/A	4	Analyst Upgrade Gap Up High Trading Volume
PYXS Pyxis Oncology	3.6502 of 5 stars	$1.72 +1.5%	$6.83 +298.4%	+46.7%	$108.02M	$13.86M	N/A	60	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DARE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dare Bioscience (DARE) Competitors

DARE vs. ENGN, BDTX, LIXT, PYXS, and PLYX

How does Dare Bioscience compare to enGene?

Summary

How does Dare Bioscience compare to Black Diamond Therapeutics?

Summary

How does Dare Bioscience compare to Lixte Biotechnology?

Summary

How does Dare Bioscience compare to Pyxis Oncology?

Summary

How does Dare Bioscience compare to Polaryx Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dare Bioscience (DARE) Competitors

DARE vs. ENGN, BDTX, LIXT, PYXS, and PLYX

How does Dare Bioscience compare to enGene?

Which has more volatility and risk, ENGN or DARE?

Do analysts recommend ENGN or DARE?

Do institutionals and insiders hold more shares of ENGN or DARE?

Does the media prefer ENGN or DARE?

Which has preferable valuation & earnings, ENGN or DARE?

Is ENGN or DARE more profitable?

Summary

How does Dare Bioscience compare to Black Diamond Therapeutics?

Does the media prefer BDTX or DARE?

Which has more volatility & risk, BDTX or DARE?

Do insiders and institutionals hold more shares of BDTX or DARE?

Which has higher valuation & earnings, BDTX or DARE?

Is BDTX or DARE more profitable?

Do analysts recommend BDTX or DARE?

Summary

How does Dare Bioscience compare to Lixte Biotechnology?

Does the media favor DARE or LIXT?

Do analysts prefer DARE or LIXT?

Which has higher valuation & earnings, DARE or LIXT?

Do institutionals and insiders believe in DARE or LIXT?

Is DARE or LIXT more profitable?

Which has more risk and volatility, DARE or LIXT?

Summary

How does Dare Bioscience compare to Pyxis Oncology?

Do analysts prefer DARE or PYXS?

Does the media prefer DARE or PYXS?

Do insiders & institutionals believe in DARE or PYXS?

Which has more volatility & risk, DARE or PYXS?

Is DARE or PYXS more profitable?

Which has higher earnings & valuation, DARE or PYXS?

Summary

How does Dare Bioscience compare to Polaryx Therapeutics?

Is PLYX or DARE more profitable?

Do analysts rate PLYX or DARE?

Does the media favor PLYX or DARE?

Which has better valuation & earnings, PLYX or DARE?

Do insiders and institutionals believe in PLYX or DARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools